BridgeMD
New treatment option for Stimulant Use
Official title Neuromodulation and Cognitive Training for Substance Use Disorders
ClinicalTrials.gov ID: NCT04426214
What this study is testing
- What it's testing
- The relapsing nature of substance use disorder is a major obstacle to successful treatment. About 70% of those entering treatment will relapse within one year.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 65
You may be able to join if
- Abstinent from any substance or alcohol use (excluding caffeine or nicotine) for a minimum of 3 weeks at study enrollment
- Has the intention to remain in their treatment program(s) until the end of the intervention portion of the study.
- Able to provide written consent and comply with study procedures.
- Meets the MINI 7 diagnostic criteria for either stimulant use disorder (SUD) or alcohol use disorder (AUD).
You likely can't join if
- Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, HIV)
- Over 9 months of abstinence from substance use
- A head injury resulting in a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI)
- Presence of a condition that would render study measures difficult or impossible to administer or interpret
- Age outside the range of 18 to 65
- Primary current substance use disorder diagnosis (according to MINI 7 diagnostic criteria) for a substance other than stimulant or alcohol, except...
See the full eligibility criteria
- Abstinent from any substance or alcohol use (excluding caffeine or nicotine) for a minimum of 3 weeks at study enrollment
- Has the intention to remain in their treatment program(s) until the end of the intervention portion of the study.
- Able to provide written consent and comply with study procedures.
- Meets the MINI 7 diagnostic criteria for either stimulant use disorder (SUD) or alcohol use disorder (AUD).
- Any medical condition or treatment with neurological sequelae (i.e. stroke, tumor, HIV)
- Over 9 months of abstinence from substance use
- A head injury resulting in a loss of consciousness exceeding 30 minutes (i.e., moderate or severe TBI)
- Presence of a condition that would render study measures difficult or impossible to administer or interpret
- Age outside the range of 18 to 65
- Primary current substance use disorder diagnosis (according to MINI 7 diagnostic criteria) for a substance other than stimulant or alcohol, except for caffeine or nicotine (Nicotine use will be recorded but is not...
- Entrance to the treatment program under a court mandate. (i.e. legally incarcerated)
- History of ECT or cortical energy exposure within the past 6 months, including participation in any other neuromodulation studies
The study team makes the final eligibility decision.
Where it's taking place
- Minneapolis, Minnesota, United States
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 65 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Minneapolis, Minnesota, United States. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.